Chlorotrianisene

氯烯雌醚

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameChlorotrianisene
Drug Alias Nameclorotrianiseno三对甲氧苯氯乙烯chlorotrianisenumTaceNSC-10108
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptors agonists
TargetsEstrogen receptors
Therapy Area/IndicationsMenopausal symptomsHypogonadismUterine Hemorrhage +[7] 
Global Approved IndicationsHypogonadismUterine HemorrhageProstatic Hyperplasia
Approved Indications in ChinaHypogonadismUterine HemorrhageProstatic Hyperplasia
Original Approved Country/TerritoryMainland China
Original Approved Date1984/01/01
Country/TerritoryEgyptIndiaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou First Pharmaceutical Co Ltd
Inactive CompaniesTanta UniversityAll India Institute Of Medical Sciences, New DelhiFudan University +[5] 
Active IndicationsHypogonadismUterine HemorrhageProstatic Hyperplasia
Inactive IndicationsMenopausal symptomsProstatic NeoplasmsLiver Neoplasms +[4] 

Other Information

ATC CodeG03CA06
Related LinksWikipediaDrugBankKEGG